4.2 Advanced Diabetes: Insulin Regimens, CGM & Hypoglycemia
Key Takeaways
- Basal insulin is initiated at 10 units/day or 0.1–0.2 units/kg/day and titrated by 2 units every 3 days to achieve fasting plasma glucose 80–130 mg/dL; postprandial excursions warrant stepwise addition of prandial insulin (basal-plus to basal-bolus) or GLP-1 RA combination.
- Second-generation ultra-long basal insulins (degludec U-100/U-200, glargine U-300) demonstrate flat, peakless pharmacokinetic profiles extending beyond 24 to 42 hours, significantly reducing nocturnal hypoglycemia compared to first-generation glargine U-100 or detemir.
- Intensive prandial management utilizes the 500 Rule for Insulin-to-Carbohydrate Ratio (ICR = 500 / TDD) and the 1800/1500 Rule for Correction Factor / Insulin Sensitivity Factor (ISF = 1800 / TDD for rapid-acting, 1500 / TDD for regular insulin).
- Ambulatory Glucose Profile (AGP) core CGM metrics require Time in Range (TIR 70–180 mg/dL) >70% (>50% in older/high-risk adults), Time Below Range (TBR <70 mg/dL) <4%, and TBR <54 mg/dL <1%, with Glucose Management Indicator (GMI) reflecting estimated average A1C.
- Acute hypoglycemia is staged as Level 1 (<70 mg/dL), Level 2 (<54 mg/dL), and Level 3 (severe cognitive impairment); conscious patients apply the Rule of 15, while unconscious/incapacitated patients receive emergency glucagon (nasal Baqsimi 3 mg, subcutaneous auto-injectors Gvoke or Zegalogue).
4.2 Advanced Diabetes: Insulin Regimens, CGM & Hypoglycemia
BCACP Exam Anchor: Advanced diabetes management requires precision in insulin pharmacokinetic profiles, mathematical mastery of intensive basal-bolus calculations (Total Daily Dose, Insulin-to-Carbohydrate Ratio, and Correction Sensitivity Factor), expert interpretation of standardized Continuous Glucose Monitoring (CGM) Ambulatory Glucose Profiles, and immediate execution of modern hypoglycemia protocols.
1. Insulin Formulations & Pharmacokinetic Profiles
Exogenous insulin regimens are designed to replicate physiologic pancreatic insulin secretion: constant, low-level basal secretion suppressing hepatic gluconeogenesis overnight and between meals, combined with rapid prandial spikes in response to ingested carbohydrates.
| Insulin Category | Formulations & Brand Names | Onset | Peak | Effective Duration | Clinical Nuances & Pearls |
|---|---|---|---|---|---|
| Ultra-Rapid Acting | Lispro-aabc (Lyumjev)<br/>Aspart-fast (Fiasp) | 1–5 min | 45–60 min | 3–5 hours | Co-formulated with excipients (citrate/treprostinil or niacinamide) to accelerate vascular permeability. Administer at start of meal or up to 20 min after. |
| Rapid-Acting | Lispro (Humalog U-100/U-200)<br/>Aspart (Novolog)<br/>Glulisine (Apidra) | 10–20 min | 1–2 hours | 3–5 hours | Standard prandial bolus. Administer 10–15 min prior to meal. Ideal for pump therapy (CSII). |
| Short-Acting (Regular) | Regular Human (Humulin R, Novolin R U-100)<br/>U-500 Regular (Humulin R U-500) | 30–60 min<br/>(U-500: 30 min) | 2–4 hours<br/>(U-500: 4–8 hr) | 6–8 hours<br/>(U-500: 12–24 hr) | U-100 regular given 30 min before meals. U-500 Regular acts as both basal and bolus in severe insulin resistance (TDD >200 units/day); dose with dedicated U-500 syringe or pen. |
| Intermediate-Acting | NPH (Humulin N, Novolin N) | 1–2 hours | 4–8 hours | 14–18 hours | Cloudy suspension (requires rolling/mixing). Erratic absorption; high risk of nocturnal hypoglycemia if given at bedtime. |
| Long-Acting Basal (1st Gen) | Glargine U-100 (Lantus, Basaglar, Semglee)<br/>Detemir (Levemir) | 1–2 hours | Relatively peakless | 20–24 hours<br/>(Detemir: 14–20 hr) | Acidic pH (cannot mix in same syringe with other insulins). Detemir often requires BID dosing at low doses (<0.4 units/kg/day). |
| Ultra-Long Basal (2nd Gen) | Degludec U-100/U-200 (Tresiba)<br/>Glargine U-300 (Toujeo SoloStar/Max) | 30–90 min | Truly flat / peakless | >42 hours (Degludec)<br/>~36 hours (Glargine U-300) | Forms multi-hexamer subcutaneous depots. Lowest nocturnal hypoglycemia risk. Degludec offers flexible day-to-day administration timing (min 8 hours between doses). Glargine U-300 requires ~10–15% higher dose when converting from U-100. |
2. Regimen Design & Stepwise Intensification in T2D
When non-insulin agents (metformin, SGLT2i, GLP-1 RA) fail to achieve glycemic targets, insulin therapy is intensified in a stepwise manner:
Non-Insulin Therapies (GLP-1 RA / SGLT2i / Metformin)
│
▼
Initiate Basal Insulin Monotherapy
10 units/day OR 0.1-0.2 units/kg/day once daily
│
▼
Titrate Basal Dose Treat-to-Target
Increase by 2 units every 3 days to FPG 80-130 mg/dL
│
▼
Check for "Overbasalization"
(Basal dose >0.5 units/kg/day, high bedtime-to-morning
glucose differential, high glucose variability, hypoglycemia)
│
┌─────────────────────────────┴─────────────────────────────┐
▼ ▼
Add GLP-1 RA (if not already used) Intensify to Prandial Bolus Therapy
Fixed-Ratio Combinations (iGlarLixi / iDegLira) 1. Basal-Plus: Add 4 units or 10% basal
High glycemic efficacy with weight/hypo mitigation prior to largest meal of the day
2. Basal-Bolus: Add prandial before 2-3 meals
Clinical Overbasalization Signals
Escalating basal insulin beyond 0.5 units/kg/day without addressing postprandial glucose surges leads to clinical overbasalization. Warning signs include:
- Basal insulin dose $>0.5\text{ units/kg/day}$ (approaching $>0.7–1.0\text{ units/kg/day}$).
- Bedtime-to-morning glucose differential $>50\text{ mg/dL}$ (bedtime glucose significantly higher than fasting morning glucose).
- Frequent hypoglycemia alongside persistent A1C elevation.
- High glycemic variability.
- Action: Stop escalating basal insulin. Initiate prandial insulin (Basal-Plus or Basal-Bolus) or add a GLP-1 receptor agonist.
3. Advanced Intensive Insulin Calculations
In patients managed on intensive basal-bolus therapy or continuous subcutaneous insulin infusion (CSII insulin pump), pharmacists must precisely calculate prandial coverage and correction boluses:
Total Daily Dose (TDD) Estimation
- Initial TDD Estimate: $0.4\text{ to } 0.6\text{ units/kg/day}$ (use $0.1–0.3\text{ units/kg/day}$ for frail/elderly/CKD; $0.6–1.0+\text{ units/kg/day}$ in severe insulin resistance/obesity).
- Basal / Bolus Split: Typically 50% Basal and 50% Prandial (divided equally among 3 meals).
Insulin-to-Carbohydrate Ratio (ICR) — The 500 Rule
Represents the grams of carbohydrate covered by 1 unit of rapid-acting insulin: (Note: For regular insulin, use the 450 Rule: $450 / \text{TDD}$).
Insulin Sensitivity Factor (ISF) / Correction Factor (CF) — The 1800 Rule
Represents the anticipated drop in blood glucose (mg/dL) produced by 1 unit of rapid-acting insulin: (Note: For regular insulin, use the 1500 Rule: $1500 / \text{TDD}$).
Comprehensive Bolus Dose Calculation Formula
4. Continuous Glucose Monitoring (CGM) & AGP Interpretation
Standardized Continuous Glucose Monitoring provides an Ambulatory Glucose Profile (AGP) that reveals dynamic glycemic patterns, glycemic variability, and occult hypoglycemia.
| CGM Metric | Target for Standard Adults (T1D & T2D) | Target for Older / Frail / High-Risk Adults | Clinical Action if Unmet |
|---|---|---|---|
| Time in Range (TIR: 70–180 mg/dL) | > 70% (>16 hours 48 minutes/day) | > 50% (>12 hours/day) | Every 10% increase in TIR reduces microalbuminuria by ~40% and retinopathy by ~35%. |
| Time Below Range (TBR Level 1: 54–69 mg/dL) | < 4.0% (<1 hour/day) | < 1.0% (<15 minutes/day) | Primary Clinical Priority: Always address and eliminate hypoglycemia before addressing hyperglycemia. |
| Time Below Range (TBR Level 2: <54 mg/dL) | < 1.0% (<15 minutes/day) | < 1.0% (<15 minutes/day) | Urgent de-escalation of insulin/sulfonylurea therapy required. |
| Time Above Range (TAR Level 1: 181–250 mg/dL) | < 25.0% (<6 hours/day) | < 50.0% (Combined TAR) | Adjust prandial/basal dosing or add non-insulin organ-protective agents. |
| Time Above Range (TAR Level 2: >250 mg/dL) | < 5.0% (<1 hour 12 minutes/day) | < 10.0% | Optimize postprandial bolus timing and ICR. |
| Coefficient of Variation (%CV) | $\le 36\%$ | $\le 36\%$ | $%\text{CV} = (\text{SD} / \text{Mean Glucose}) \times 100$. $%\text{CV} > 36\%$ indicates high glycemic instability and elevated hypoglycemia risk. |
| Glucose Management Indicator (GMI) | Correlates with laboratory A1C | Correlates with laboratory A1C | Calculated from mean CGM glucose over $\ge 14$ days: $\text{GMI (\%)} = 3.31 + (0.02392 \times \text{Mean Glucose [mg/dL]})$. |
5. Hypoglycemia Staging & Emergency Glucagon Management
ADA Classification of Hypoglycemia
- Level 1 (Mild / Alert): Measurable glucose $54\text{ to } 69\text{ mg/dL}$. Patient is fully conscious and symptomatic (tremor, diaphoresis, palpitations, hunger).
- Level 2 (Moderate / Clinically Significant): Glucose $<54\text{ mg/dL}$. Immediate neuroglycopenic risk; triggers acute counter-regulatory hormone response.
- Level 3 (Severe): Characterized by severe cognitive or physical impairment requiring external third-party assistance for recovery, regardless of the numeric glucose reading.
Acute Treatment Protocols
Suspected Hypoglycemia
│
▼
Check Blood Glucose
│
┌────────────────────────┴────────────────────────┐
▼ ▼
Conscious & Able to Swallow Unconscious / Incapacitated / Seizing
(Level 1 or Level 2) (Level 3)
│ │
▼ ▼
"Rule of 15" Emergency Glucagon Administration
1. Ingest 15-20g fast-acting carbs 1. Nasal Baqsimi (3 mg powder in 1 nostril) OR
(4 oz juice/soda, 4 glucose tabs, 2. SubQ Gvoke (1 mg autoinjector) OR
1 tube glucose gel, 8 oz skim milk) 3. SubQ Zegalogue (0.6 mg autoinjector)
2. Rest and wait 15 minutes 4. Call 911 immediately
3. Recheck blood glucose 5. Turn patient on side (recovery position)
4. If BG <70 mg/dL → Repeat 15g carbs 6. Feed carbohydrate meal once awake
5. If BG ≥70 mg/dL → Eat meal/snack
Modern Ready-to-Use Emergency Glucagon Formulations
Historical reconstituted glucagon kits (vial and syringe requiring multi-step mixing) have high failure rates during emergency crises. Modern stable formulations are preferred:
- Nasal Glucagon (Baqsimi 3 mg): Single-use nasal powder device. Passively absorbed across nasal mucosa; does not require inhalation or active sniffing. Effective even in patients with rhinitis or nasal congestion.
- Liquid Stable Glucagon Autoinjector / Prefilled Syringe (Gvoke HypoPen 1 mg for adults, 0.5 mg for pediatrics): Ready-to-inject room-temperature subcutaneous injection (thigh, abdomen, outer arm).
- Dasiglucagon Autoinjector / Prefilled Syringe (Zegalogue 0.6 mg SubQ): Fast-acting synthetic peptide glucagon receptor agonist with rapid glycemic recovery (median time 10 minutes).
A 42-year-old male with type 1 diabetes weighing 80 kg is managed on an intensive basal-bolus insulin regimen with insulin degludec and insulin lispro. His Total Daily Dose (TDD) of insulin is 50 units/day. He is planning to consume a dinner containing 75 grams of carbohydrates. His pre-meal fingerstick blood glucose is 230 mg/dL, and his target preprandial blood glucose is 110 mg/dL. Using the 500 Rule for carbohydrate ratio and the 1800 Rule for correction factor, what is the total dose of insulin lispro he should administer before dinner?
An 76-year-old female with long-standing T2D, mild cognitive impairment, and history of falls wears a CGM. Her 14-day Ambulatory Glucose Profile (AGP) reveals: Sensor active 94%, Mean glucose 162 mg/dL, Glucose Management Indicator (GMI) 7.2%, Time in Range (70–180 mg/dL) 62%, Time Below Range (<70 mg/dL) 7%, Time Below Range (<54 mg/dL) 2.5%, and %CV 41%. She is currently taking insulin glargine U-100 28 units at bedtime and glipizide 10 mg BID. Which of the following is the most urgent clinical priority?
A 28-year-old female with type 1 diabetes is found by her roommate unresponsive, diaphoretic, and unable to swallow. The roommate calls 911. Which of the following is the most appropriate emergency intervention for the roommate to administer immediately?